Neil William Aubuchon

Chief Commercial Officer

Neil William Aubuchon (Chief Commercial Officer) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Viking Therapeutics, Inc. (VKTX). Across 1 priced purchase filing, the average 21-session return was +0.5% from execution and +0.5% from disclosure (delay-adjusted; derived). The largest single filing was $150K of VKTX (4,475 sh × $33.50, as filed), executed Mar 10.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+0.5%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+0.5%

same 1 filings, from disclosure

Filings, ttm

1 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$150K

shares × price, as filed

Last traded

Mar 10

Filed Mar 10

Median ADV $77.4M across their filed names

Open performance→

Volume by month

Buys $150K Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names

VKTX

Viking Therapeutics, Inc. VKTX · 1 buy · 0 sells 1 filing

Recent filings

VKTXPURCHASE Viking Therapeutics, Inc. View filing → $150K
4,475 sh × $33.50
Exec Mar 10
Filed Mar 10 · 6:20 PM ET